Anktiva FDA approval date

The FDA approved Anktiva (N-803) on 22 Apr 2024.

FDA approval date
22 Apr 2024

Drug identity checked against registry records

Also recorded as N-803; NAI; Nogapendekin Alfa Inbakicept

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study to Examine Anktiva for the Treatment of COVID-19.NCT07123727IBRXPhase 2Recruiting2027-03Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2024-04-22DayAnktivaFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761336", "applicant_as_listed_by_fda": "ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU", "brand_names": ["ANKTIVA"], "active_ingredients": ["nogapendekin alfa inbakicept-pmln"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20240422", "matched_on": "drug name equals FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026